Intelligent Bio Solutions Inc.

NasdaqCM:INBS Stock Report

Market Cap: US$7.3m

Intelligent Bio Solutions Management

Management criteria checks 4/4

Intelligent Bio Solutions' CEO is Harry Simeonidis, appointed in Oct 2022, has a tenure of 1.58 years. total yearly compensation is $343.30K, comprised of 80.4% salary and 19.6% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $891.19. The average tenure of the management team and the board of directors is 5.1 years and 3.8 years respectively.

Key information

Harry Simeonidis

Chief executive officer

US$343.3k

Total compensation

CEO salary percentage80.4%
CEO tenure1.6yrs
CEO ownership0.01%
Management average tenure5.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

GBS acquires Intelligent Fingerprinting in all-stock deal

Oct 04

GBS GAAP EPS of -$0.57, revenue of $0.44M

Aug 31

GBS Inc.: Can Its Technology Come Through?

Aug 31

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

Aug 09

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Jul 29
Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Harry Simeonidis's remuneration changed compared to Intelligent Bio Solutions's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$13m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023US$343kUS$276k

-US$11m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022n/an/a

-US$5m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022US$355kUS$250k

-US$8m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021n/an/a

-US$9m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021US$351kUS$240k

-US$7m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020n/an/a

-US$4m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020US$207kUS$157k

-US$3m

Compensation vs Market: Harry's total compensation ($USD343.30K) is below average for companies of similar size in the US market ($USD663.90K).

Compensation vs Earnings: Harry's compensation has been consistent with company performance over the past year.


CEO

Harry Simeonidis (56 yo)

1.6yrs

Tenure

US$343,298

Compensation

Mr. Harry Simeonidis serves as Chief Executive Officer of Intelligent Bio Solutions Inc. since October 2022 and serves as its President since October 26, 2022. He had been Non-Executive Director of FarmaFo...


Leadership Team

NamePositionTenureCompensationOwnership
Harry Simeonidis
President & CEO1.6yrsUS$343.30k0.012%
$ 891.2
Spiro Sakiris
Chief Financial Officer5.1yrsUS$304.91k0.69%
$ 49.9k
Victoria Gavrilenko
Operations Manager5.8yrsUS$45.00kno data
Alex Arzeno
VP of Investor Relationsno datano datano data

5.1yrs

Average Tenure

56yo

Average Age

Experienced Management: INBS's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lawrence Fisher
Independent Director3.8yrsUS$37.80k0.0022%
$ 161.6
Christopher Towers
Independent Director3.8yrsUS$47.80k0.029%
$ 2.1k
Jonathan Hurd
Independent Director6.1yrsUS$37.80k0.0022%
$ 161.6
Stephen Boyages
Chairman3.8yrsUS$114.17k0.011%
$ 801.6
Jason Isenberg
Independent Director1.6yrsUS$22.30kno data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Board: INBS's board of directors are considered experienced (3.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.